Nobuya Ishii

Kamakura, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.

YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.

Journal: Cancer research

Published: October 26, 2018

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 20, 2018

Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.

Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.

Journal: Molecular cancer therapeutics

Published: November 21, 2017

Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.

Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.

Journal: Journal of medicinal chemistry

Published: December 10, 2016

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.

Journal: The Journal of clinical investigation

Published: June 14, 2016

ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.

ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.

Journal: Molecular cancer therapeutics

Published: June 12, 2015

Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.

Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.

Journal: Molecular cancer therapeutics

Published: October 24, 2014

Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma.

Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma.

Journal: PloS one

Published: October 23, 2014

The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.

The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.

Journal: Molecular cancer therapeutics

Published: August 30, 2014

A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell line.

A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell line.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: August 22, 2014

Inhibition of metastasis of rhabdomyosarcoma by a novel neutralizing antibody to CXC chemokine receptor-4.

Inhibition of metastasis of rhabdomyosarcoma by a novel neutralizing antibody to CXC chemokine receptor-4.

Journal: Cancer science

Published: April 14, 2014

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.

Journal: Cancer cell

Published: August 29, 2013

Showing 1-12 of 17

Last Updated: 09/26/2026